GMED Stock Cash Flow Statements

Globus Medical Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Free Cash Flow

Capital Expenditure

Globus Medical Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30

cash flows from operating activities:
net income	202,846,000	75,462,000	26,505,000	51,836,000	31,760,000	-7,117,000	15,034,000	998,000	57,712,000	49,129,000	50,065,000	47,430,000	54,590,000	38,084,000	15,106,000	47,211,000	41,545,000	45,329,000	52,957,000	44,216,000	-20,837,000	25,949,000	45,529,000	38,307,000	38,164,000	33,210,000	36,750,000	35,208,000	44,978,000	39,538,000	24,376,000	25,591,000	28,667,000	28,714,000	24,298,000	26,227,000	25,806,000	28,010,000	37,601,000	26,481,000	24,054,000	24,648,000	27,638,000	23,061,000	20,647,000	21,139,000	20,985,000	20,310,000	7,426,000	19,891,000	20,767,000	16,487,000
adjustments to reconcile net income to net cash from operating activities:
bargain purchase gain
acquired in-process research and development			0	0	0	12,613,000													0	0
depreciation and amortization	70,631,000	66,074,000	68,228,000	66,947,000	63,588,000	55,261,000	71,162,000	37,388,000	18,075,000	18,108,000	16,910,000	17,578,000	16,927,000	16,837,000	16,829,000	16,751,000	19,130,000	17,157,000	16,904,000	16,301,000	15,101,000	14,568,000	14,046,000	13,575,000	12,859,000	12,254,000	11,936,000	10,461,000	9,757,000	9,476,000	8,294,000	10,838,000	10,695,000	12,240,000	17,235,000	7,838,000	7,022,000	6,676,000	6,415,000	6,090,000	5,905,000	5,674,000	5,697,000	5,373,000	5,387,000	5,297,000	5,186,000	4,859,000	4,742,000	4,610,000	4,608,000	4,612,000
amortization of premiums on marketable securities	0	-421,000	-516,000	-105,000	-38,000	24,000
benefit from excess and obsolete inventory	4,973,000	5,960,000	7,165,000	5,696,000	6,584,000	3,914,000
amortization of inventory fair value step-up	5,966,000	49,000
amortization of 2025 notes fair value step-up	0	6,658,000
stock-based compensation expense	13,617,000	13,206,000	11,907,000	12,211,000	12,813,000	17,260,000	12,445,000	22,755,000	8,589,000	8,953,000	8,507,000	8,314,000	7,837,000	8,152,000	7,805,000	7,451,000	7,632,000	7,698,000	5,935,000	7,020,000	7,311,000	6,807,000	6,438,000	6,898,000	6,301,000	6,448,000	4,821,000	5,545,000	5,480,000	6,053,000	4,027,000	3,597,000	3,571,000	3,491,000	2,945,000	2,747,000	2,920,000	2,770,000	2,704,000
allowance for expected credit losses	1,348,000	3,206,000	1,319,000
change in fair value of business acquisition liabilities	5,222,000	167,000	17,913,000	-4,131,000	12,904,000	-165,000	13,003,000	1,151,000	3,726,000	-446,000	7,175,000	-653,000	-1,127,000	-263,000	2,471,000	208,000	13,870,000	258,000	1,647,000	564,000	-43,000	506,000	1,208,000	0	0	579,000	393,000	176,000	182,000	234,000
change in deferred income taxes	-41,745,000	509,000	-33,179,000	-27,448,000	-20,184,000	-45,091,000	-11,799,000	-34,830,000	-7,181,000	-3,979,000	-5,209,000	-9,075,000	-4,945,000	-2,994,000	-14,484,000	-1,348,000	-975,000	-808,000	120,000	-3,331,000	1,768,000	-2,895,000	1,868,000	1,010,000	365,000	1,059,000	-635,000	177,000	1,553,000	-124,000	7,477,000	5,053,000	-1,839,000	-2,399,000	-2,454,000	-2,981,000	1,234,000	391,000	10,350,000	932,000	-2,830,000	-2,217,000	736,000	-884,000	-1,816,000	-2,415,000
(gain)/loss on disposal of assets	3,518,000	2,613,000	2,865,000	2,223,000	430,000	34,000	75,000	1,337,000	48,000	81,000	58,000	41,000	85,000	115,000	81,000	192,000	88,000	103,000	95,000	89,000	418,000	207,000	348,000	223,000	201,000	94,000	137,000	253,000
payment of business acquisition-related liabilities	-13,752,000	-2,012,000	-679,000	-1,119,000	-850,000	-16,115,000
net (gain)/income from foreign currency adjustment	-7,570,000	-3,772,000	27,566,000	-8,912,000	-4,633,000	11,191,000
increase in:
accounts receivable	-2,208,000	22,603,000	22,483,000	23,661,000	-87,813,000	-36,393,000	-12,961,000	-8,716,000	-18,376,000	-9,861,000	-4,643,000	-15,976,000	-28,610,000	-1,614,000	-5,967,000	5,659,000	-5,241,000	-20,346,000	2,284,000	-10,894,000	5,175,000	14,131,000	-12,939,000	1,165,000	-3,999,000	-2,533,000	-18,889,000	-643,000	2,823,000	-5,080,000	-22,755,000	972,000	-947,000	-2,225,000	-7,779,000	487,000	423,000	2,201,000	-725,000	-5,059,000	-297,000	1,888,000	-11,781,000	1,605,000	-1,679,000	-812,000	-7,469,000	2,267,000	1,787,000	-6,197,000	-1,609,000	-2,227,000
inventories	-4,135,000	-7,587,000	-11,887,000	4,882,000	-13,869,000	-8,986,000	-11,350,000	-20,320,000	-16,188,000	-22,470,000	-13,095,000	-17,229,000	-13,482,000	-17,939,000	-2,810,000	-3,137,000	-2,027,000	-3,997,000	-2,840,000	-12,900,000	-22,263,000	-12,108,000	-9,149,000	-12,775,000	-14,250,000	-13,844,000	-8,340,000	-11,922,000	-9,914,000	-1,206,000	1,679,000	-2,304,000	-2,550,000	-2,102,000	-3,894,000	-2,797,000	-1,560,000	-2,252,000	-2,329,000	-5,347,000	-4,290,000	-7,361,000	-5,466,000	-3,041,000	-5,501,000	-3,993,000	-963,000	-2,760,000	-5,946,000	-7,009,000	-5,954,000	-5,258,000
prepaid expenses and other assets	-3,682,000	4,534,000	4,167,000	-1,107,000	-3,779,000	1,778,000	2,428,000	820,000	-2,936,000	836,000	-3,426,000	-8,134,000	721,000	547,000	-5,384,000	-1,639,000	-3,671,000	4,516,000	-6,707,000	-1,506,000	-2,670,000	-205,000	-9,219,000	-111,000	-3,781,000	848,000	-7,415,000	3,222,000	-2,069,000	-1,234,000	-3,800,000	-9,480,000	-122,000	8,628,000	-2,764,000	6,218,000	-95,000	1,209,000	165,000	-471,000	-1,793,000	896,000	1,076,000	-941,000	-623,000	239,000	1,514,000	-365,000	-896,000	-850,000	209,000	958,000
accounts payable	-3,186,000	-899,000	16,369,000	-10,267,000	17,314,000	-5,753,000	-6,271,000	-5,183,000	-6,685,000	3,916,000	4,011,000	-1,968,000	8,215,000	4,160,000	1,163,000	-216,000	-1,475,000	4,212,000	-11,753,000	2,427,000	3,257,000	-283,000	931,000	743,000	-3,728,000	2,827,000	1,850,000	893,000	-6,479,000	728,000	10,187,000	1,316,000	-1,488,000	-172,000	3,403,000	-1,719,000	-469,000	-1,238,000	-1,013,000	-2,746,000	-901,000	835,000	6,881,000	-1,432,000	275,000	-1,096,000	818,000	779,000	563,000	-320,000	3,014,000	-1,789,000
accrued expenses and other liabilities	14,817,000	-28,658,000	4,634,000	29,340,000	4,930,000	-33,881,000	-3,452,000	21,467,000	9,081,000	-9,969,000	4,427,000	9,068,000	8,020,000	-15,428,000	10,396,000	3,941,000	8,342,000	-4,783,000	13,859,000	11,505,000	5,946,000	-13,702,000	5,818,000	9,969,000	1,240,000	-9,984,000	16,693,000	139,000	4,968,000	-7,072,000	7,313,000	-4,880,000	5,673,000	-10,170,000	12,014,000	-20,100,000	5,583,000	-15,661,000	-12,207,000	6,107,000	3,839,000	-3,904,000	163,000	3,470,000	2,400,000	-2,015,000	7,324,000	3,815,000	21,314,000	-5,490,000	4,819,000	1,441,000
income taxes payable/receivable	-58,234,000	19,608,000	-8,501,000	-11,653,000	-33,740,000	40,517,000	-13,794,000	10,339,000	-13,393,000	16,440,000	-2,177,000	1,254,000	-14,944,000	12,980,000	15,037,000	694,000	-22,600,000	12,081,000	1,762,000	-5,135,000	-2,833,000	7,863,000	8,658,000	-3,840,000	-11,932,000	6,441,000	4,403,000	4,952,000	-17,773,000	7,497,000	2,937,000	116,000	-20,318,000	13,493,000	-9,000	12,439,000	-20,313,000	14,517,000	-382,000	-462,000	-14,036,000	14,223,000	-5,155,000	4,452,000	-11,993,000	7,875,000	6,035,000	7,425,000	-20,091,000	10,853,000	-4,910,000	3,481,000
net cash provided by/(used in) operating activities	77,865,000	177,300,000	210,339,000	203,654,000	54,258,000	52,387,000	104,674,000	50,484,000	35,028,000	53,313,000	63,975,000	32,920,000	36,883,000	44,690,000	76,253,000
cash flows from investing activities:
purchases of marketable securities	0	-1,750,000	-100,138,000	-1,192,000	-4,157,000	-8,017,000	0	-19,262,000	-12,240,000	-69,141,000	-97,434,000	-143,004,000	-36,951,000	-142,145,000	-275,302,000	-53,965,000	-107,982,000	-185,110,000	-166,122,000	0	0	-57,418,000	-69,080,000	-66,840,000	-82,695,000	-127,911,000	-155,595,000	-73,124,000	-190,820,000	-118,403,000	-189,286,000	-84,413,000	-67,981,000	-51,215,000	-63,640,000	-50,737,000	-68,678,000	-104,208,000	-90,300,000	-63,716,000	-70,817,000	-72,874,000	-90,273,000	-56,134,000	-29,672,000	-75,343,000	-54,144,000	-42,686,000	-50,875,000	-93,187,000
maturities of marketable securities	0	58,630,000	10,920,000	26,037,000	21,624,000	85,000	25,760,000	55,102,000	73,782,000	85,546,000	73,095,000	68,554,000	64,023,000	106,549,000	56,022,000	40,147,000	91,889,000	39,850,000	33,632,000	12,447,000	16,617,000	71,766,000	41,190,000	44,250,000	71,114,000	90,454,000	67,983,000	51,964,000	84,772,000	73,330,000	73,900,000	63,720,000	47,453,000	55,280,000	70,747,000	81,643,000	59,839,000	69,656,000	57,384,000	45,874,000	20,870,000	64,574,000	40,360,000	48,915,000	49,042,000	46,250,000	21,560,000	15,100,000
sales of marketable securities	0	115,608,000	2,207,000	2,240,000	4,839,000	2,565,000	317,736,000	198,199,000	8,548,000	13,240,000	12,455,000	23,323,000	23,982,000	42,673,000	27,016,000	24,728,000	24,336,000	33,818,000	28,953,000	22,539,000	12,031,000	5,374,000	7,312,000	20,984,000	13,717,000	11,773,000	21,154,000	21,493,000	62,408,000	1,333,000	110,946,000	2,063,000	2,998,000	6,505,000	5,693,000	30,507,000	8,804,000	7,798,000	11,664,000	6,979,000	19,321,000	19,764,000	3,709,000	6,873,000	2,875,000	14,280,000	8,658,000
purchases of property and equipment	-46,562,000	-36,103,000	-17,111,000	-41,952,000	-27,798,000	-28,568,000	-22,881,000	-21,534,000	-17,868,000	-15,991,000	-18,340,000	-11,983,000	-23,753,000	-19,971,000	-17,045,000	-17,795,000	-8,386,000	-13,672,000	-14,063,000	-17,325,000	-9,956,000	-22,314,000	-15,793,000	-12,062,000	-14,740,000	-28,155,000	-17,159,000	-15,371,000	-14,793,000	-12,374,000	-13,425,000	-12,817,000	-13,528,000	-11,533,000	-14,208,000	-6,559,000	-10,776,000	-9,366,000	-14,154,000	-11,480,000	-17,898,000	-7,228,000	-9,095,000	-3,428,000	-6,067,000	-6,164,000	-5,205,000	-5,519,000	-6,184,000	-6,772,000	-7,652,000	-5,183,000
acquisition of businesses, net of cash acquired and purchases of intangible and other assets			0	-100,000	-4,886,000	-12,649,000	0	-293,366,000	0	-2,662,000	-30,260,000	0	-175,000	-1,000,000									336,000	0
acquisition of intangible assets	0	-5,000,000
proceeds from credit facility
repayment of borrowings from credit facility
net cash provided by/(used in) investing activities	-299,108,000	131,385,000	-104,122,000	-14,967,000	-10,378,000	-46,584,000	320,615,000	-80,861,000	52,222,000	10,992,000	-60,484,000	-63,110,000	27,126,000	-13,894,000	-243,797,000
cash flows from financing activities:
net proceeds from exercise of stock options	4,697,000	11,223,000	69,283,000	23,505,000	14,238,000	3,413,000
payments related to tax withholdings for share-based compensation	-660,000	-2,293,000	66,000	-840,000	-612,000	-5,343,000
repurchase of common stock	-25,000,000	-190,451,000	-1,000,000	0	-1,471,000	-83,316,000					0	0							0	0	-30,805,000	-73,864,000
repayment of senior convertible notes	0	-449,985,000
net cash provided by/(used in) financing activities	-24,937,000	-635,396,000	59,733,000	19,583,000	8,709,000	-115,721,000	-237,270,000	1,425,000	1,084,000	2,940,000	13,591,000	13,162,000	-142,762,000	6,047,000	-1,023,000															3,867,000																			4,953,000	788,000	5,460,000
effect of foreign exchange rates on cash	14,360,000	3,539,000	-4,278,000	4,072,000	3,773,000	-3,312,000	-347,000	2,120,000	433,000	-26,000	-839,000	479,000	-264,000	-123,000		38,000	-39,000	-569,000
net increase/(decrease) in cash and cash equivalents	-231,820,000	-323,172,000	161,672,000	212,342,000	56,362,000	-113,230,000	187,672,000	-26,832,000	88,767,000	67,219,000	16,243,000	-16,549,000																							42,447,000	-5,150,000	14,067,000	21,123,000		8,942,000	-33,447,000	-7,259,000	-87,184,000	32,949,000	31,898,000	14,640,000	-11,945,000	9,593,000	-39,229,000	-80,857,000
cash and cash equivalents at beginning of period	0	784,438,000	0	0	0	467,292,000	0	0	0	150,466,000	0	0	0	193,069,000
cash and cash equivalents at end of period	-231,820,000	461,266,000	161,672,000	212,342,000	56,362,000	354,062,000	187,672,000	-26,832,000	88,767,000	217,685,000	16,243,000	-16,549,000	-79,017,000	229,789,000
supplemental disclosures of cash flow information:
income taxes paid	86,027,000	7,199,000	41,034,000	45,888,000	69,619,000	1,967,000	35,422,000	26,192,000	37,255,000	1,724,000	19,522,000	21,605,000	36,124,000	572,000	5,577,000	7,853,000	31,027,000	570,000	6,109,000	17,181,000	356,000	1,791,000	83,000	10,081,000	22,525,000	1,450,000	5,658,000	2,227,000	21,470,000	1,197,000	10,103,000	13,533,000	32,819,000	2,656,000	13,078,000	4,795,000	31,440,000	774,000	11,145,000	14,075,000	31,371,000	509,000	14,734,000	9,240,000	23,954,000	3,168,000	7,763,000	5,065,000	25,473,000	418,000	8,558,000	12,895,000
non-cash investing and financing activities:
accrued purchases of property and equipment	3,440,000	10,014,000	4,479,000	-4,706,000	4,082,000	5,426,000	1,129,000
equity issued in conjunction with the nuvasive merger							0
amortization of inventory fair value step up				60,756,000	53,671,000	53,670,000	52,591,000
amortization of 2025 note fair value step up				6,658,000	6,657,000	6,658,000
allowance for doubtful accounts					8,513,000	2,968,000	-626,000	2,421,000	1,053,000	810,000	395,000	132,000	200,000	-728,000	317,000	293,000	510,000	80,000	219,000	286,000	1,699,000	756,000	294,000	1,503,000	1,196,000	33,000	569,000	76,000	95,000	217,000	583,000	177,000	164,000	794,000	365,000	172,000	60,000	88,000	508,000	240,000	670,000	47,000	82,000	124,000	23,000	89,000	459,000	145,000	35,000	54,000	27,000	21,000
payment of business acquisition related liabilities							-635,000	-880,000	-718,000	-772,000	-626,000	-922,000	-356,000	-743,000			-1,568,000	-1,537,000	0
amortization of premium (discount) on marketable securities								-56,000	304,000	482,000	943,000	1,238,000	1,518,000	1,690,000	1,018,000	632,000	611,000	520,000	372,000	111,000	84,000	20,000	-81,000	-272,000	-340,000	-396,000
write-down for excess and obsolete inventories								2,728,000	1,917,000	2,055,000	510,000	1,822,000	2,234,000	1,834,000					5,330,000	5,195,000	6,537,000	679,000	559,000	-529,000	301,000	2,167,000	2,149,000	2,920,000	2,923,000	2,483,000	3,361,000	3,196,000	3,291,000	1,671,000	5,917,000	2,383,000	2,311,000	2,225,000	2,802,000	2,392,000
(increase)/decrease in:
increase/(decrease) in:
payment of business acquisition liabilities								-1,874,000	-2,115,000	-1,919,000	-1,897,000	-1,735,000	-1,854,000	-1,699,000							-287,000	-566,000	-501,000	-463,000	-283,000	-5,350,000	-226,000	-563,000	-510,000	-5,440,000	-4,875,000	0	-233,000	-5,001,000	-5,004,000	0	-100,000	-300,000	-300,000	-300,000	-300,000	-300,000	-300,000	-300,000	-400,000	-200,000	-300,000	-300,000	-300,000	-400,000	-300,000	-200,000
proceeds from exercise of stock options								3,299,000	3,199,000	4,859,000	15,488,000	14,897,000	3,585,000	7,746,000	3,563,000	24,336,000	26,496,000	9,101,000	28,201,000	28,157,000	10,201,000	5,763,000	11,686,000	7,082,000	2,013,000	10,255,000	3,064,000	3,114,000	23,824,000	9,307,000	4,792,000	1,032,000	3,921,000	1,990,000	1,446,000	853,000	1,680,000	1,895,000	1,164,000	1,298,000
purchases of property and equipment included in accounts payable and accrued expenses									-1,127,000	6,493,000	2,082,000	322,000	914,000	4,105,000	1,060,000	-46,000	917,000	2,620,000	279,000
net increase in cash and cash equivalents														36,720,000																		5,186,000	-32,766,000	49,796,000																	17,244,000
effect of foreign exchange rate on cash																			486,000	461,000	-66,000	-16,000	75,000	-417,000	226,000	-40,000	-60,000	-125,000	-1,042,000	971,000	1,201,000	328,000	129,000	321,000	430,000	-2,443,000	28,000	91,000	36,000	82,000	-6,000	41,000	140,000	162,000	-61,000	-56,000	32,000	163,000	-3,000	38,000	-14,000	-24,000
net increase in cash, cash equivalents, and restricted cash															-168,807,000	93,093,000	83,935,000	-54,549,000	-11,210,000			-28,982,000	29,534,000	48,400,000	-12,186,000	-9,771,000		25,351,000	108,000	1,019,000
cash, cash equivalents, and restricted cash at beginning of period															0	0	0	239,397,000	0	0	0	195,724,000	0	0	0	139,747,000	0	0	0	118,817,000
cash, cash equivalents, and restricted cash at end of period															-168,807,000	93,093,000	83,935,000	184,848,000	-11,210,000	85,053,000	-1,188,000	166,742,000	29,534,000	48,400,000	-12,186,000	129,976,000	-5,548,000	25,351,000	108,000	119,836,000
write-down of excess and obsolete inventories																570,000	3,450,000	1,550,000
acquisition of businesses, net of cash acquired, and purchases of intangible and other assets																											0
net cash from operating activities																	59,189,000	63,570,000	80,184,000	53,248,000	23,068,000	42,293,000	54,309,000	55,866,000	22,597,000	39,203,000	44,291,000	51,788,000	33,269,000	52,295,000	44,837,000	35,273,000	25,976,000	53,449,000	51,896,000	41,934,000	23,016,000	55,047,000	44,080,000	30,046,000	13,161,000	34,670,000	1,945,000	35,645,000	12,350,000	29,232,000	32,658,000	33,557,000	8,980,000	18,276,000	19,450,000	22,189,000
capex																	-7,469,000	-11,052,000	-13,784,000	-17,325,000	-9,956,000	-22,314,000	-15,793,000	-12,062,000	-14,740,000	-28,155,000	-17,159,000	-15,371,000	-14,793,000	-12,374,000	-13,425,000	-12,817,000	-13,528,000	-11,533,000	-14,208,000	-6,559,000	-10,776,000	-9,366,000	-14,154,000	-11,480,000	-17,898,000	-7,228,000	-9,095,000	-3,428,000	-6,067,000	-6,164,000	-5,205,000	-5,519,000	-6,184,000	-6,772,000	-7,652,000	-5,183,000
free cash flows																	51,720,000	52,518,000	66,400,000	35,923,000	13,112,000	19,979,000	38,516,000	43,804,000	7,857,000	11,048,000	27,132,000	36,417,000	18,476,000	39,921,000	31,412,000	22,456,000	12,448,000	41,916,000	37,688,000	35,375,000	12,240,000	45,681,000	29,926,000	18,566,000	-4,737,000	27,442,000	-7,150,000	32,217,000	6,283,000	23,068,000	27,453,000	28,038,000	2,796,000	11,504,000	11,798,000	17,006,000
net cash from investing activities																	-143,000	-125,114,000	-119,092,000	7,661,000	-3,299,000	-2,592,000	-36,035,000	-13,668,000	-36,739,000	-53,839,000	-52,617,000	-28,863,000	-55,433,000	-56,114,000	-16,308,000	-31,447,000	-62,559,000	-963,000	-6,408,000	-46,214,000	-10,811,000	-36,120,000	-35,406,000	-22,840,000	-48,525,000	-43,779,000	-91,427,000	-3,774,000	16,178,000	-20,977,000	-45,906,000	-28,126,000	-53,159,000	-99,959,000	-7,652,000	-11,214,000
net cash provided by/used in financing activities																	24,928,000	7,564,000
collections/(issuance) of note receivable
proceeds from sale of assets																											1,000,000	1,000,000
net cash used in/provided by financing activities																			27,212,000	23,683,000
net increase/(decrease) in cash, cash equivalents, and restricted cash
interest paid																					6,000	1,000	22,000	53,000	2,000	2,000					-31,000	13,000	13,000	8,000	12,000	21,000	1,000	1,000	0	0			0	7,000	12,000	13,000	54,000	12,000	13,000	17,000	24,000	13,000
net cash from financing activities																						-68,667,000	11,185,000	6,619,000	1,730,000	4,905,000	2,838,000	2,551,000			-83,000	1,032,000			-3,471,000	1,573,000	1,834,000	2,105,000	941,000	1,654,000	1,923,000	1,809,000	2,158,000	916,000	3,431,000	6,441,000
impairment of intangible assets
amortization of premium on marketable securities																											-131,000	331,000	692,000	785,000	413,000	403,000	847,000	1,008,000	1,001,000	982,000	1,132,000	953,000	1,002,000	982,000	730,000	640,000	607,000	507,000
non-cash settlement of accrued expenses
acquisition of businesses, net of cash acquired																															1,557,000	0			0				0	-497,000	-1,000	-48,015,000
change in fair value of contingent consideration																																	333,000	478,000																	96,000	63,000
restricted cash																															0	478,000			-1,000	10,758,000	-784,000	15,668,000	-734,000	-703,000
accounts payable to related party																																															-630,000	-1,915,000	1,323,000	1,322,000	-2,281,000	4,354,000
issuance of note receivable																																			-5,000,000
cash and cash equivalents, beginning of period																															-65,685,000	0	0	132,639,000	0	0	0	60,152,000	0	0	0	82,265,000	0	0	0	89,962,000	0	0	0	212,400,000	0	0
cash and cash equivalents, end of period																															-36,038,000	5,186,000	-32,766,000	182,435,000	42,447,000	-5,150,000	14,067,000	81,275,000	9,651,000	8,942,000	-33,447,000	75,006,000	-87,184,000	32,949,000	31,898,000	104,602,000	-11,945,000	9,593,000	-39,229,000	131,543,000	17,244,000	29,579,000
net cash (used in)/provided by financing activities																																		-3,011,000
excess tax benefit related to nonqualified stock options																																			-87,000	-720,000	-254,000	-510,000	-77,000	-656,000	-2,001,000	684,000	364,000	203,000	1,055,000	2,786,000	237,000	2,332,000	1,884,000	303,000	5,305,000	-2,701,000
accounts payable to related-party																																								0	0	-5,359,000		-214,000	319,000	1,184,000
net decrease in cash and cash equivalents
stock-based compensation																																									2,538,000	2,131,000	1,900,000	1,661,000	1,623,000	1,927,000	1,312,000	1,387,000	1,166,000	1,312,000	953,000	1,545,000
benefit from excess and obsolete inventories																																										2,529,000	1,523,000	1,904,000	1,722,000	1,813,000	1,807,000	2,942,000	1,463,000	2,000,000	733,000	1,686,000
proceeds from issuance of common stock																																										1,425,000		1,013,000	2,776,000	3,855,000
adjustments to reconcile net income to net cash from operating activities
acquisition of businesses																																																			0
net proceeds from initial public offering																																																			-3,000
net proceeds from issuance of common stock																																															1,334,000	1,967,000	3,369,000	885,000	458,000
repayments of long-term debt
purchase of common stock
deferred income taxes																																																-5,332,000	-3,906,000	-1,900,000		-3,185,000
acquisition of business
change in fair value of interest rate swap
sales of short-term investments
net proceeds from issuance of common and preferred stock

We provide you with 20 years of cash flow statements for Globus Medical stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Globus Medical stock. Explore the full financial landscape of Globus Medical stock with our expertly curated income statements.

The information provided in this report about Globus Medical stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.